AU2002216028A1 - Novel carbamate-substituted pyrazolopyridine derivatives - Google Patents

Novel carbamate-substituted pyrazolopyridine derivatives

Info

Publication number
AU2002216028A1
AU2002216028A1 AU2002216028A AU1602802A AU2002216028A1 AU 2002216028 A1 AU2002216028 A1 AU 2002216028A1 AU 2002216028 A AU2002216028 A AU 2002216028A AU 1602802 A AU1602802 A AU 1602802A AU 2002216028 A1 AU2002216028 A1 AU 2002216028A1
Authority
AU
Australia
Prior art keywords
pyrazolopyridine derivatives
novel carbamate
substituted pyrazolopyridine
substituted
carbamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002216028A
Inventor
Cristina Alonso-Alija
Klaus Dembowsky
Achim Feurer
Dietmar Flubacher
Dieter Lang
Elisabeth Perzborn
Elke Stahl
Johannes-Peter Stasch
Alexander Straub
Stefan Weigand
Frank Wunder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2002216028A1 publication Critical patent/AU2002216028A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AU2002216028A 2000-11-22 2001-11-09 Novel carbamate-substituted pyrazolopyridine derivatives Abandoned AU2002216028A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10057751A DE10057751A1 (en) 2000-11-22 2000-11-22 New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
DE10057751 2000-11-22
PCT/EP2001/012966 WO2002042300A1 (en) 2000-11-22 2001-11-09 Novel carbamate-substituted pyrazolopyridine derivatives

Publications (1)

Publication Number Publication Date
AU2002216028A1 true AU2002216028A1 (en) 2002-06-03

Family

ID=7664120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002216028A Abandoned AU2002216028A1 (en) 2000-11-22 2001-11-09 Novel carbamate-substituted pyrazolopyridine derivatives

Country Status (8)

Country Link
US (2) US7105523B2 (en)
EP (1) EP1339717B1 (en)
JP (1) JP4295506B2 (en)
AU (1) AU2002216028A1 (en)
CA (1) CA2429309A1 (en)
DE (2) DE10057751A1 (en)
ES (1) ES2236360T3 (en)
WO (1) WO2002042300A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10057751A1 (en) * 2000-11-22 2002-05-23 Bayer Ag New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
DE10122894A1 (en) * 2001-05-11 2002-11-14 Bayer Ag New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
DE10220570A1 (en) * 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
DE10224462A1 (en) * 2002-06-03 2003-12-11 Bayer Ag Use of cGMP stimulating compounds
WO2004002531A1 (en) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
DE10242941A1 (en) * 2002-09-16 2004-03-18 Bayer Ag New 2-(pyrazolo-(3,4-b)-pyridinyl)-5-pyridinyl-4-pyrimidinylamine derivative, is a soluble guanylate cyclase stimulant useful e.g. for treating cardiovascular diseases, hypertension or ischemia
DE10244810A1 (en) * 2002-09-26 2004-04-08 Bayer Ag New morpholine-bridged indazole derivatives
WO2004041274A1 (en) * 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
CN101274911B (en) * 2003-06-17 2011-01-26 艾尼纳制药公司 Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases
EP1644347A1 (en) * 2003-06-20 2006-04-12 Arena Pharmaceuticals, Inc. N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES
PE20050483A1 (en) 2003-10-31 2005-08-25 Arena Pharm Inc TETRAZOLE DERIVATIVES OF FORMULA (I), ITS PHARMACEUTICAL COMPOSITIONS AND PROCESSES TO PRODUCE PHARMACEUTICAL COMPOSITIONS
CN102631349A (en) 2004-12-23 2012-08-15 艾尼纳制药公司 5ht2c receptor modulator compositions and methods of use
DE102006043443A1 (en) 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
DE102006054757A1 (en) * 2006-11-21 2008-05-29 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
DE102007026392A1 (en) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Solutions for the perfusion and preservation of organs and tissues
EP2288585A1 (en) * 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
WO2010065275A1 (en) * 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102008063992A1 (en) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. New aliphatic substituted pyrazolopyridines and their use
DE102009004245A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use
UY33041A (en) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
SI3415515T1 (en) 2009-11-27 2020-03-31 Adverio Pharma Gmbh Method for the preparation of methyl-(4,6-diamino-2-(1-(2-fluorobenzyl)-1h-pyrazolo(3,4-b)pyridin-3-yl)pyrimidin-5-yl)methylcarbamate
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2552915B1 (en) * 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
DE102010021637A1 (en) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
WO2012030957A2 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
CN103189359A (en) 2010-09-01 2013-07-03 艾尼纳制药公司 Salts of lorcaserin with optically active acids
EP2611449A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
ES2704455T3 (en) 2010-09-01 2019-03-18 Arena Pharm Inc Pharmaceutical forms of modified release of 5-HT2C agonists useful for weight management
DE102010043379A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use
DE102010043380A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituted carbamates and their use
CN102485724B (en) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 Substituted thiophene base pyrazolo-pyridines and medicinal use thereof
MY168412A (en) 2011-11-25 2018-11-09 Adverio Pharma Gmbh Method for producing substituted 5-fluoro-1h-pyrazolopyridines
RU2674670C1 (en) 2012-10-09 2018-12-12 Арена Фармасьютикалз, Инк. Method of correction of body mass
SG11201506211RA (en) 2013-02-21 2015-09-29 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
TN2017000465A1 (en) 2015-05-06 2019-04-12 Bayer Pharma AG The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
WO2017013010A1 (en) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof
CA3006764A1 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
CN110022871A (en) 2016-10-11 2019-07-16 拜耳制药股份公司 Combination product comprising sGC stimulant and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EA202092680A1 (en) 2018-05-15 2021-04-13 Байер Акциенгезельшафт 1,3-THIAZOL-2-YL-SUBSTITUTED BENZAMIDES FOR TREATMENT OF DISEASES ASSOCIATED WITH SENSITIZATION OF NERVOUS FIBERS
AU2019301683A1 (en) 2018-07-11 2021-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochonrial disorders
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19642255A1 (en) 1996-10-14 1998-04-16 Bayer Ag Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives
EP0934311B1 (en) 1996-10-14 2009-05-13 Bayer HealthCare AG New heterocyclylmethyl-substituted pyrazol derivates
DE19649460A1 (en) 1996-11-26 1998-05-28 Bayer Ag New substituted pyrazole derivatives
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834044A1 (en) * 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19834045A1 (en) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine
DE19834047A1 (en) * 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19846514A1 (en) 1998-10-09 2000-04-20 Bayer Ag New arylmethyl and heterocyclylmethyl substituted heteroaryl-indazole derivatives useful in treatment of cardiovascular, ischemic and urogenital disorders
DE10057751A1 (en) * 2000-11-22 2002-05-23 Bayer Ag New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation

Also Published As

Publication number Publication date
EP1339717A1 (en) 2003-09-03
JP2004517827A (en) 2004-06-17
DE50105334D1 (en) 2005-03-17
US7291622B2 (en) 2007-11-06
CA2429309A1 (en) 2002-05-30
US20040082596A1 (en) 2004-04-29
WO2002042300A1 (en) 2002-05-30
US20050261323A1 (en) 2005-11-24
ES2236360T3 (en) 2005-07-16
JP4295506B2 (en) 2009-07-15
DE10057751A1 (en) 2002-05-23
US7105523B2 (en) 2006-09-12
EP1339717B1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
AU2002221827A1 (en) Novel lactame-substituted pyrazolopyridine derivatives
AU2002216028A1 (en) Novel carbamate-substituted pyrazolopyridine derivatives
AU2001295992A1 (en) Imidazopyridine derivatives
AU2002220692A1 (en) Novel pyridine-substituted pyrazolopyridine derivatives
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2002352142A1 (en) Pyrazolopyridine derivatives
EG24669A (en) Antivral azaindole derivatives
AU2002227919A1 (en) Novel sulfonamide-substituted pyrazolopyridine derivatives
AU2002349676A1 (en) 4-oxoquinoline derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2001264280A1 (en) Vitamin D derivatives
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU5256301A (en) Froindazole derivative
AU2001248777A1 (en) Vitamin d derivatives
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001286191A1 (en) Quinolizine derivatives